MedPath

Conbercept

Generic Name
Conbercept
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
1227158-72-6
Unique Ingredient Identifier
1P05PW62F3
Background

Conbercept has been investigated for the basic science of Age-related Macular Degeneration.

Indication

用于治疗湿性年龄相关性黄斑变性(AMD)。

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy

Not Applicable
Not yet recruiting
Conditions
Retinopathy of Prematurity (ROP)
Interventions
Drug: Conbercept
First Posted Date
2024-12-05
Last Posted Date
2024-12-05
Lead Sponsor
Wang Yusheng
Target Recruit Count
146
Registration Number
NCT06717412

Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy

Phase 4
Recruiting
Conditions
Diabetic Macular Edema
Interventions
Drug: Conbercept
First Posted Date
2024-03-12
Last Posted Date
2024-07-23
Lead Sponsor
Shanghai Eye Disease Prevention and Treatment Center
Target Recruit Count
58
Registration Number
NCT06305143
Locations
🇨🇳

Shanghai Eye Diseases Prevention &Treatment Center, Shanghai, Shanghai, China

Conbercept for Polypoidal Choroidal Vasculopathy（START Study）

Completed
Conditions
Polypoidal Choroidal Vasculopathy
Conbercept
First Posted Date
2022-02-08
Last Posted Date
2022-02-08
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
500
Registration Number
NCT05229237
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, China

Anti-VEGF in Real-world

Conditions
Neovascular Age-related Macular Edema
Proliferative Diabetic Retinopathy
Diabetic Macular Edema
Choroidal Neovascular Membrane
Non-proliferative Diabetic Retinopathy
Retinal Vein Occlusion
Interventions
Drug: Ranibizumab
Drug: Aflibercept
Drug: Conbercept
First Posted Date
2022-02-03
Last Posted Date
2022-02-03
Lead Sponsor
Wenbin Wei
Target Recruit Count
1000
Registration Number
NCT05222633
Locations
🇨🇳

Wen-Bin Wei, Beijing, Beijing, China

Effects of Adding Triamcinolone Acetonide to Conbercept Treatment for Refractory Diabetic Macular Edema (CONTE)

Not Applicable
Conditions
Diabetes Mellitus, Type 2
Macular Edema
Interventions
Drug: Conbercept and TA
Drug: Conbercept
First Posted Date
2020-11-13
Last Posted Date
2020-11-17
Lead Sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University
Target Recruit Count
50
Registration Number
NCT04627402
Locations
🇨🇳

Zhongshan Opthalmic Center, Guangzhou, Guangdong, China

Application of Intravitreal Conbercept Injection as a Primary Treatment for Exudative Circumscribed Choroidal Haemangioma

Early Phase 1
Conditions
Circumscribed Choroidal Haemangioma
Interventions
Drug: conbercept
First Posted Date
2019-06-04
Last Posted Date
2019-06-04
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
50
Registration Number
NCT03973125
Locations
🇨🇳

Kunbei Lai, Guangzhou, Guangdong, China

PRP vs PRP+IVC for Severe nPDR

Not Applicable
Conditions
Severe Nonproliferative Diabetic Retinopathy
Diabete Mellitus
Diabetic Retinopathy
Interventions
Drug: Conbercept
Procedure: Panretinal coagulation
First Posted Date
2019-03-05
Last Posted Date
2019-03-05
Lead Sponsor
Ruijin Hospital
Target Recruit Count
40
Registration Number
NCT03863535
Locations
🇨🇳

Ruijin Hospital, Shanghai, Shanghai, China

Safety and Effectiveness of Intravitreal Conbercept for Exudative Circumscribed Choroidal Haemangioma

Early Phase 1
Conditions
Circumscribed Choroidal Haemangioma
Interventions
Drug: conbercept
First Posted Date
2018-06-27
Last Posted Date
2018-06-27
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
50
Registration Number
NCT03571282
Locations
🇨🇳

Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China

Intravitreal Conbercept After Vitrectomy

Early Phase 1
Completed
Conditions
Early Proliferative Diabetic Retinopathy
Interventions
Drug: Conbercept
First Posted Date
2018-02-08
Last Posted Date
2019-04-30
Lead Sponsor
Tianjin Medical University Eye Hospital
Target Recruit Count
50
Registration Number
NCT03426540

The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)

Phase 4
Conditions
Polypoidal Choroidal Vasculopathy (PCV)
Interventions
Drug: Conbercept
First Posted Date
2017-05-19
Last Posted Date
2017-07-19
Lead Sponsor
Chengdu Kanghong Biotech Co., Ltd.
Target Recruit Count
300
Registration Number
NCT03159884
Locations
🇨🇳

The Scond Xiangya Hospital of Central South University, Changsha, China

🇨🇳

Beijing Tongren Hospital,Cmu, Beijing, China

🇨🇳

Tianjin Medical University Eye Hospital, Tianjin, China

and more 32 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy